Triamcinolone, bevacizumab yield similar VA outcomes in cataract patients with DME

SAN DIEGO — No significant difference in best correctedvisual acuity was seen when patients with diabetic macular edema at the time ofcataract surgery were given either triamcinolone or bevacizumab, according to aspeaker here.“The poorest visual outcomes are seen in those withdiabetic macular edema at the time of surgery,” said Salmaan Al-Qureshi, MBBS, FRANZCO, who presented 6-month resultsfrom the DiMECAT trial at the American Society of Retina Specialists annualmeeting. “Despite the advances in treatment, there is very little evidenceregarding the use of anti-VEGF or triamcinolone in cataract surgery.”

Full Story →